Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 15.3% in February

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 75,300 shares, a decrease of 15.3% from the February 13th total of 88,900 shares. Currently, 11.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 49,500 shares, the short-interest ratio is currently 1.5 days.

Qualigen Therapeutics Stock Down 3.9 %

NASDAQ QLGN traded down $0.13 on Wednesday, hitting $3.08. 1,302 shares of the company were exchanged, compared to its average volume of 99,178. Qualigen Therapeutics has a 1-year low of $2.96 and a 1-year high of $29.44. The firm has a 50 day moving average of $3.52 and a two-hundred day moving average of $5.18.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.